Pulsenmore (PLSM)
Builds prescription-connected home ultrasound systems for remote clinician review.
Something off on this page? Send us feedback.
Provides prescription smartphone-connected home ultrasound systems, combining devices, guided apps, cloud transfer, and clinician dashboards for remote review. Revenue has centered on Pulsenmore ES and Israeli healthcare organizations, while U.S. use remains tied to prescribed, physician-interpreted care.
Combines a handheld prenatal ultrasound cradle with a mobile app, cloud service, and clinician dashboard. Pulsenmore ES lets prescribed patients acquire limited images at home while clinicians interpret them remotely; its FDA-authorized U.S. use is confined to fetal-heart-rate assessment in singleton pregnancies and does not replace routine or emergency care.
Sells chiefly through Israeli HMOs and hospitals, then uses specialist practices and virtual-maternity partners to enter the United States; activity also reaches Australia, Europe, and other markets. Pulsenmore FC supports home fertility monitoring in early Israeli commercialization, while Pulsenmore MC remains in clinical-feasibility development for lung-fluid monitoring.
Relies on provider prescriptions, physician review, compatible smartphones, cloud connectivity, regulatory authorization, reimbursement pathways, and component suppliers across Israel and East Asia.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $23.1M · Total debt $11.4M · Total assets $33.1M · Shareholders' equity $16.0M
- Revenue
- $2.1M
- Operating income
- −$7.2M
- Net income
- −$12.1M
Reported in ILS, converted at the latest exchange rate
No dividends on record.
| Insiders | 30.99% | 2.01M shares | |
|---|---|---|---|
| 3 holders · as of Apr 28, 2026 | |||
| Other | 69.01% | 4.49M shares | |
| remainder | |||
6.50M company shares as of Sep 15, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Elazar SonnenscheinInsiderdirector, officer: Chief Executive Officer | 28.79% | 1.87M | filed Apr 28, 2026 |
Jonathan AderethInsiderdirector | 1.98% | 129,062 | filed Mar 18, 2026 |
Meir ShmouelyInsiderofficer: VP Software Development | 0.21% | 13,812 | filed Mar 18, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- GE HealthCare
Wireless handheld ultrasound and clinician workflow in obstetric care.
- Butterfly Network
Smartphone-connected ultrasound and cloud workflow in obstetric care.
- Philips (ADR)
App-based handheld ultrasound for OB/GYN and maternal-care access.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pulsenmore | $2.54 | +7.17% | $15.4M | — | — | 1.0 | — |
| GE HealthCare | $66.02 | −0.38% | $29.93B | 19.2 | 12.7 | 1.5 | +5.8% |
| Butterfly Network | $9.65 | −2.82% | $2.64B | — | — | 23.6 | +39.5% |
| Philips (ADR) | $24.57 | −1.62% | $24.41B | 18.9 | 12.8 | 1.2 | −2.8% |
| Median | 19.0 | 12.7 | 1.5 | +5.8% |